VANCOUVER, British Columbia, June 06, 2023 Xenon Pharmaceuticals Inc. , a neurology-focused biopharmaceutical company, today announced that the company will present at the Goldman Sachs 44th. | June 6, 2023
XEN1101 Phase 3 epilepsy program continues to make significant progress across all ongoing clinical trials including the recent initiation of X-TOLE3 in addition to the ongoing X-TOLE2 and X-ACKT. | May 9, 2023
BURNABY, British Columbia, April 21, 2023 Xenon Pharmaceuticals Inc. , a neurology-focused biopharmaceutical company, today announced that it will host a company presentation at the 2023 Bloom. | April 21, 2023
BURNABY, British Columbia, April 18, 2023 Xenon Pharmaceuticals Inc. , a neurology-focused biopharmaceutical company, today announced that the company will present at the 22nd Annual Needham. | April 18, 2023
BURNABY, British Columbia, Feb. 14, 2022 Xenon Pharmaceuticals Inc. , a neurology-focused biopharmaceutical company, today announced its participation in one-on-one investor meetings and a. | February 14, 2022